Atherosclerosis and Lipoproteins |
From Leibniz-Institute for Arteriosclerosis Research at the University Hospital of Muenster (O.H., B.L., G.W.P., H.R.); the Department of Cardiology and Angiology (G.W.P.), Hospital of the University of Muenster, Germany; the Department of Thoracic and Cardiovascular Surgery (H.E., G.W.P.), Hospital of the University of Muenster, Germany; and Imperial College London (N.J.S.), National Heart and Lung Institute, London, UK.
Correspondence to Oliver Hofnagel, Leibniz-Institute for Arteriosclerosis Research, Department of Cell Biology and Ultrastructure Research, Muenster, 48149 Germany. E-mail hofnagel{at}uni-muenster.de
Background LOX-1, a receptor for oxidized low-density lipoprotein (OxLDL), seems to play a critical role in foam cell formation of macrophages (M
s) and smooth muscle cells (SMC). Inhibition of LOX-1 expression reduces foam cell formation and might influence lipid core formation in atherosclerotic lesions. Because statins are able to downregulate LOX-1 expression in vitro, we examined if pravastatin can be used to reduce LOX-1 expression and lipid core formation in lesions of Watanabe heritable hyperlipidemic (WHHL) rabbits.
Methods and Results Pravastatin downregulated LOX-1 expression in cultured human M
s and in cultured human aortic SMCs. Homozygous WHHL rabbits were treated with 50 mg kg1 d1 pravastatin for 32 weeks. Immunohistochemical studies revealed that LOX-1 was expressed in intimal M
s and SMCs of atherosclerotic lesions. The pravastatin-treated rabbits showed, compared with untreated rabbits, a significantly reduced LOX-1 protein and mRNA expression in the aortic arch. Lipid labeling of this aorta region also demonstrated a strong reduction of the ratio of lipid core area/total lesion area in pravastatin-treated rabbits.
Conclusions The in vivo inhibition of LOX-1 expression by pravastatin demonstrated here represents a new pleiotropic effect of pravastatin. This in vivo inhibition of LOX-1 might be one mechanism for the lipid core reducing effect of pravastatin in atherogenesis.
The scavenger receptor LOX-1 seems to play a critical role in foam cell formation of macrophages and smooth muscle cells. Our study demonstrated in vivo inhibition of LOX-1 expression by pravastatin. This new pleiotropic effect of pravastatin might be one mechanism for the lipid core reducing effect of pravastatin in atherogenesis.
Key Words: atherosclerosis cardiovascular disease prevention lipoproteins oxidized lipids smooth muscle cells
This article has been cited by other articles:
![]() |
J. Lu, J.-H. Yang, A. R. Burns, H.-H. Chen, D. Tang, J. P. Walterscheid, S. Suzuki, C.-Y. Yang, T. Sawamura, and C.-H. Chen Mediation of Electronegative Low-Density Lipoprotein Signaling by LOX-1: A Possible Mechanism of Endothelial Apoptosis Circ. Res., March 13, 2009; 104(5): 619 - 627. [Abstract] [Full Text] [PDF] |
||||
![]() |
M Ethier-Chiasson, J-C Forest, Y Giguere, A Masse, C Marseille-Tremblay, E Levy, and J Lafond Modulation of placental protein expression of OLR1: implication in pregnancy-related disorders or pathologies Reproduction, October 1, 2008; 136(4): 491 - 502. [Abstract] [Full Text] [PDF] |
||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2006 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |